Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.76 USD | -1.11% | +10.50% | +190.75% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 5.5M | Capitalization | 347M |
---|---|---|---|---|---|
Net income 2024 * | -67M | Net income 2025 * | -77M | EV / Sales 2024 * | - |
Net cash position 2024 * | 217M | Net cash position 2025 * | - | EV / Sales 2025 * | 63.1 x |
P/E ratio 2024 * |
-4.96
x | P/E ratio 2025 * |
-5.86
x | Employees | 45 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.39% |
Latest transcript on Jasper Therapeutics, Inc.
1 day | +0.77% | ||
1 week | +7.92% | ||
Current month | -3.56% | ||
1 month | +6.62% | ||
3 months | +21.54% | ||
6 months | +265.98% | ||
Current year | +191.76% |
Managers | Title | Age | Since |
---|---|---|---|
Ronald Martell
CEO | Chief Executive Officer | 62 | 22-03-14 |
Herbert Cross
DFI | Director of Finance/CFO | 52 | 23-09-21 |
Luca Di Noto
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ronald Martell
CEO | Chief Executive Officer | 62 | 22-03-14 |
Thomas Wiggans
CHM | Chairman | 72 | Oct. 31 |
Kurt von Emster
BRD | Director/Board Member | 56 | 21-09-23 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-20 | 22.94 | -0.35% | 24 051 |
24-05-17 | 23.02 | +0.77% | 65,738 |
24-05-16 | 22.84 | +5.76% | 77,712 |
24-05-15 | 21.6 | +3.25% | 101,371 |
24-05-14 | 20.92 | +0.77% | 39,212 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+191.76% | 347M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+13.79% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- JSPR Stock